A5010494320- Cytomegalovirus and herpesvirus research
- Renal Transplantation Outcomes and Treatments
- Herpesvirus Infections and Treatments
- Neurological Complications and Syndromes
- Organ Transplantation Techniques and Outcomes
- Polyomavirus and related diseases
- Organ Donation and Transplantation
- Parvovirus B19 Infection Studies
- Renal cell carcinoma treatment
- Renal and Vascular Pathologies
- Dialysis and Renal Disease Management
- Organ and Tissue Transplantation Research
- Toxoplasma gondii Research Studies
- Transplantation: Methods and Outcomes
- SARS-CoV-2 and COVID-19 Research
- Renal and related cancers
- Viral-associated cancers and disorders
- Central Venous Catheters and Hemodialysis
- Blood Coagulation and Thrombosis Mechanisms
- COVID-19 Clinical Research Studies
- COVID-19 Impact on Reproduction
- Vascular Procedures and Complications
- Atrial Fibrillation Management and Outcomes
- Erythropoietin and Anemia Treatment
- Mycobacterium research and diagnosis
Charles University
2011-2023
University Hospital Plzen
2002-2008
Both preemptive therapy and universal prophylaxis are used to prevent cytomegalovirus (CMV) disease after transplantation. Randomized trials comparing both strategies sparse. Renal transplant recipients at risk for CMV (D+/R-, D+/R+, D-/R+) were randomized 3-month with valacyclovir (2 g q.i.d., n = 34) or valganciclovir (900 mg b.i.d. a minimum of 14 days, 36) significant DNAemia (>/=2000 copies/mL by quantitative PCR in whole blood) assessed weekly 16 weeks 5, 6, 9 12 months. The 12-month...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination may fail to sufficiently protect transplant recipients against disease 2019 (COVID-19). We retrospectively evaluated COVID-19 in kidney (n = 226) after BNT162b2 vaccine administration. The control group consisted of unvaccinated patients 194) during the previous pandemic wave. measured anti-spike protein immunoglobulin G (IgG) levels and cellular responses, using enzyme-linked immunosorbent spot assay, a...
Cytomegalovirus (CMV) is a risk factor for acute renal allograft rejection. The aim of this study was to determine the impact CMV viremia on subclinical rejection (SCR) and interstitial fibrosis tubular atrophy (IF/TA) in protocol biopsy at 3 months after transplantation.A total 118 consecutive transplant recipients (donor recipient seropositive) were included followed up prospectively. Protocol biopsies with sufficient tissue obtained 102 patients. activity monitored using real-time...
Prevention of cytomegalovirus (CMV) is essential in organ transplantation. The two main strategies are pre-emptive therapy, which one screens for and treats asymptomatic CMV viremia, universal antiviral prophylaxis. We compared these examined long-term outcomes a randomized, open-label, single-center trial. randomly assigned 70 renal transplant recipients (CMV-seropositive recipient or donor) to 3-month prophylaxis with valacyclovir (n=34) valganciclovir significant viremia detected at...
BackgroundKidney recipients maintaining a prolonged allograft survival in the absence of immunosuppressive drugs and without evidence rejection are supposed to be exceptional. The ERA-EDTA-DESCARTES working group together with Nantes University launched European-wide survey identify new patients, describe them estimate their frequency for first time.
Both valganciclovir and high-dose valacyclovir are recommended for cytomegalovirus prophylaxis after renal transplantation. A head-to-head comparison of both regimens is lacking. The objective the study was to compare with valganciclovir, which constituted control group.In a randomized, open-label, single-center trial, recipients transplants (recipient or donor cytomegalovirus-seropositive) were randomly allocated (1:1) 3-month (2 g four times daily) (900 mg daily). Enrollment occurred from...
Significance Statement Although cytomegalovirus (CMV) infection is an important factor in the pathogenesis of kidney allograft rejection, previous studies have not determined optimal CMV prevention strategy to avoid indirect effects virus. In this randomized trial involving 140 transplant recipients, incidence acute rejection at 12 months was lower with valganciclovir prophylaxis (for least 3 months) compared preemptive therapy initiated after detection DNA whole blood. However, associated a...
Both oral ganciclovir and valacyclovir decrease the incidence of cytomegalovirus (CMV) disease after renal transplantation. Moreover, has been shown to reduce risk acute rejection. Our study was designed compare efficacy safety in prophylaxis CMV transplantation.A total 83 patients were prospectively randomized 3-month treatment with (3 g/day, n=36, GAN) or (8 n=35, VAL). A control group (DEF, n=12) managed by deferred therapy.No differences found demography, immunosuppression,...
Thrombogenicity is one of the most important biocompatibility markers artificial material. Anticoagulation commonly used to reduce thrombogenicity extracorporeal circuit (ECC) during intermittent hemodialysis (IHD). In some situations, systemic anticoagulants are contraindicated. The aim our study was compare parameters IHD with three different methods without a anticoagulation effect. prospective, randomized, and crossover study, we examined 10 stable patients (i) regular saline flushes...
Asymptomatic cytomegalovirus (CMV) infection is associated with graft dysfunction and failure. However, no study assessed CMV viral load in terms of the risk for failure.In a prospective cohort kidney transplant recipients, we impact DNAemia on overall survival incidence moderate-to-severe interstitial fibrosis tubular atrophy (IF/TA) protocol biopsy at 36 months. was stratified by whole blood.A total 180 patients transplanted from October 2003 through January 2011 were included followed 4...
Polyomavirus BK (BKV) is the cause of polyomavirus-associated nephropathy resulting in premature graft loss. There are limited data regarding role cytomegalovirus (CMV) infection and its prevention developing BKV viremia PVAN. In a prospective study, we analyzed 207 consecutive renal transplant recipients previously enrolled 2 randomized trials evaluating different CMV regimens with routine screening for CMV. Of these, 59 received valganciclovir 100 valacyclovir prophylaxis; 48 patients were...
Background Antiviral prophylaxis against cytomegalovirus has been associated with reduced risk of allograft rejection and improved survival after renal transplantation. This phenomenon might not be fully explained by preventing the indirect effects cytomegalovirus. The effect antiviral agents on lymphocyte function in patients treated modern immunosuppression studied to date. Methods Adult transplant recipients were assigned 3-month either valganciclovir (900 mg once daily; n=19) or...
Cytomegalovirus (CMV) prophylaxis may prevent CMV indirect effects in renal transplant recipients. This study aimed to compare the efficacy of valganciclovir and valacyclovir for after transplantation with focus on chronic histologic damage within graft. From November 2007 through April 2012, adult recipients were randomized, an open-label, single-center study, at a 1:1 ratio 3-month (n = 60) or 59). The primary endpoint was moderate-to-severe interstitial fibrosis tubular atrophy assessed...
ABSTRACT Background Large international differences exist in kidney transplantation (KT) rates. We aimed to investigate which factors may explain the total, deceased donor and living KT rates over last decade. Methods experts from 39 European countries completed Kidney Transplantation Rate Survey on measures barriers their potential effect rate country. In analyses, were divided into low, middle high based at start of study period 2010. Results Experts low reported more frequently that they...
Abstract Background Kidney transplant recipients are at risk for a severe course of COVID‐19 with high mortality rate. A considerable number patients remains without satisfactory serological response after the baseline and adjuvant SARS‐CoV‐2 vaccination schedule. Methods In this prospective, randomized study, we evaluated efficacy safety one two booster doses mRNA vaccines (either mRNA‐1273 or BNT162b2) in 125 naive, adult kidney who showed an insufficient humoral (SARS‐CoV‐2 IgG <10...
The association of tuberous sclerosis complex (TSC) and autosomal dominant polycystic kidney disease (ADPKD), termed TSC2/PKD1 contiguous gene syndrome, is a result molecular defect demonstrating by deletion disrupting TSC2 PKD1. Dermatopathology this syndrome has never been addressed. We report 2 sporadic cases form with emphasis on dermatopathologic findings. Both patients presented typical phenotype TSC early-onset renal requiring transplantation in one the patients. Of total 13 cutaneous...
In a randomized study, we observed higher incidence of biopsy-proven acute rejection with pre-emptive valganciclovir therapy as compared valacyclovir prophylaxis for prevention cytomegalovirus (CMV) disease after renal transplantation (RTx). Persistence the virus within allograft could stimulate alloimmune response. The aim our study was to evaluate intragraft CMV infection in patients trial.RTx recipients at risk were (n=36) significant viraemia (> or =2,000 copies/ml by quantitative PCR...
The aim of this study was to determine the cost impact four different strategies for prevention cytomegalovirus (CMV) disease after renal transplantation.Hospitalization data and medical resource utilization were prospectively collected alongside two randomized trials. In first trial, patients 3-month prophylaxis with either oral ganciclovir (1 g t.i.d., n = 36) or valacyclovir (2 q.i.d., 35), control group (n 12) managed by deferred therapy. second randomly assigned 34) preemptive therapy...
Abstract Introduction Valganciclovir ( vGCV ) and valacyclovir vACV are used in cytomegalovirus CMV prophylaxis renal transplant recipients. The aim of this study was to compare the economic impact both regimens during 1‐year follow‐up. Methods A total 117 recipients at risk for were randomized 3‐month either with (900 mg/day, n = 60) or (8 g/day, 57) their data a pharmacoeconomic analysis. evaluation involved all direct ‐related expenses first year after transplantation. Sensitivity...
Polyomavirus BK (BKV) infection of the renal allograft causes destructive tissue injury with inflammation and subsequent fibrosis. Using a prospective cohort patients after kidney transplantation performed between 2003 2012, we investigated role BKV viraemia in development progression interstitial fibrosis tubular atrophy (IFTA). The primary outcome was moderate-to-severe IFTA assessed by protocol biopsy at 36 months. A total 207 consecutive recipients were enrolled. Of these, 57 (28%)...